JPS61103884A - 13-substituted-5-ketomilbemycin and its preparation - Google Patents

13-substituted-5-ketomilbemycin and its preparation

Info

Publication number
JPS61103884A
JPS61103884A JP22555184A JP22555184A JPS61103884A JP S61103884 A JPS61103884 A JP S61103884A JP 22555184 A JP22555184 A JP 22555184A JP 22555184 A JP22555184 A JP 22555184A JP S61103884 A JPS61103884 A JP S61103884A
Authority
JP
Japan
Prior art keywords
formula
compound
carboxylic acid
reaction
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP22555184A
Other languages
Japanese (ja)
Other versions
JPH0477752B2 (en
Inventor
Kazuo Sato
一雄 佐藤
Takao Otsu
乙 孝夫
Shigeru Mio
茂 三尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Priority to JP22555184A priority Critical patent/JPS61103884A/en
Priority to IL76816A priority patent/IL76816A/en
Priority to IL85820A priority patent/IL85820A/en
Priority to AU49045/85A priority patent/AU574852B2/en
Priority to ZA858197A priority patent/ZA858197B/en
Priority to ES548244A priority patent/ES8703475A1/en
Priority to NZ213972A priority patent/NZ213972A/en
Priority to DK492785A priority patent/DK161705C/en
Priority to KR1019850007942A priority patent/KR930005333B1/en
Priority to CA000494017A priority patent/CA1267890A/en
Priority to EP85307782A priority patent/EP0184308B1/en
Priority to DE8585307782T priority patent/DE3574974D1/en
Priority to AT85307782T priority patent/ATE49001T1/en
Publication of JPS61103884A publication Critical patent/JPS61103884A/en
Priority to US07/115,642 priority patent/US4835290A/en
Priority to IL85820A priority patent/IL85820A0/en
Priority to DK267190A priority patent/DK267190A/en
Priority to US07/644,880 priority patent/US5208349A/en
Publication of JPH0477752B2 publication Critical patent/JPH0477752B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

PURPOSE:To obtain the titled compound useful as a synthetic intermediate of miticide, insecticide and anthelmintic agent, in high yield, by reacting a 5-ketomilbemycin derivative with selenium dioxide in the presence of a carboxylic acid. CONSTITUTION:A mixture of the compounds of formula II and III can be prepared by reacting the compound of formula I (R<1> is methyl, ethyl, isopropyl or sec-butyl) with selenium dioxide in the presence of a carboxylic acid of formula R<2>-COOH (R<2> is H or lower alkyl) at 0-80 deg.C. The amounts of the compounds of formula II and III depend upon the kind of the carboxylic acid and the amount of selenium dioxide, etc. If necessary, the product can be converted completely to the compound of formula II by hydrolysis. When the compound of formula III is required, it can be prepared by separating and purifying from the reaction mixture. The compound of formula III is novel. The amount of the carboxylic acid is >=1mol, and that of selenium dioxide is 1-10mol, preferably 1-3mol per 1mol of the compound of formula I.

Description

【発明の詳細な説明】 本発明は、殺ダニ剤、殺虫剤および駆虫剤合成の重要な
中間体である、下記の一般式(1)で表わされる化合物
の製法および、一般式([)で表わされる化合物に関す
るものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing a compound represented by the following general formula (1), which is an important intermediate in the synthesis of acaricides, insecticides and anthelmintic agents, and a compound represented by the general formula ([)]. with respect to the compounds represented.

上記式中、Rはメチル基、エチル基、イソプロピル基ま
たは5ec−ブチル基を示し、Rは水素原子または低級
゛アルキル基を示す。
In the above formula, R represents a methyl group, an ethyl group, an isopropyl group, or a 5ec-butyl group, and R represents a hydrogen atom or a lower alkyl group.

上記の式(1)の化合物は、米国特許第4,423,2
09号により公知の化合物であって、殺ダニ剤、殺上記
の米国特許によれば、式(I)の化合物は、13−ヒド
ロキシ−5−メトキシミルベマイシン類を酢酸水銀で処
理し、生成するエノールエーテルを酸で処理することに
より得られる。しかしながら、この方法は、原料入手性
、反応温度等の反応条件、収率等の面で難点があり、加
えて、水銀化合物を使用することから、公害対策の配慮
が必要であって、式(1)の化合物の大量合成法として
は満足すべき方法ではない。
The compound of formula (1) above is disclosed in U.S. Patent No. 4,423,2
According to the above US patent, the compound of formula (I) is a compound known from US Pat. Obtained by treating ether with acid. However, this method has drawbacks in terms of availability of raw materials, reaction conditions such as reaction temperature, yield, etc. In addition, since a mercury compound is used, consideration must be given to pollution control, and the formula ( This is not a satisfactory method for mass synthesis of the compound 1).

本発明者等は、式(I)の化合物の合成中間体としての
重要性に鑑みて、これを有利に製造する方法について遣
々検討の結果、下記一般式([)で表わされる化合物を
、下記一般式(5)で表わされるカルボン酸の存在下に
、二酸化セレンで処理することにより効率よく式(I)
の化合物を製造することを見出した。
In view of the importance of the compound of formula (I) as a synthetic intermediate, the inventors of the present invention have conducted extensive studies on an advantageous method for producing the compound, and as a result, the compound represented by the following general formula ([)] Formula (I) can be efficiently obtained by treatment with selenium dioxide in the presence of a carboxylic acid represented by the following general formula (5).
It was discovered that the compound of

R2−C0OH(ト) 上記式中、RおよびRは前記したものと同意義である。R2-C0OH (g) In the above formula, R and R have the same meanings as defined above.

本発明の原料である式(1)の化合物は、特開昭59−
1011785号および前記米国特許に記載された公知
化合物である。
The compound of formula (1), which is the raw material of the present invention, is
No. 1,011,785 and the above-mentioned US patent.

本発明の方法によれば、式(幻の化合物を、式(5)の
カルボン酸の存在下に、二酸化セレンで処理することに
より、その13位が選択的にアリル酸化される。
According to the method of the present invention, by treating a compound of formula (phantom) with selenium dioxide in the presence of a carboxylic acid of formula (5), its 13th position is selectively allylated.

式(至)のカルボン酸のRが低級アルキル基であるとき
、Rは好適には炭素原子数1ないし4個を有する直鎖ま
たは分岐鎖状のアルキル基であり、たとえばメチル、エ
チル、プロピル、イソプロピル、ブチル、イソブチルで
ある。式(ト)のカルボン酸は、好適にはギ酸および酢
酸、さらに好適にはギ酸である。
When R in the carboxylic acid of formula (to) is a lower alkyl group, R is preferably a straight or branched alkyl group having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, Isopropyl, butyl, isobutyl. The carboxylic acid of formula (g) is preferably formic acid and acetic acid, more preferably formic acid.

本発明の方法において、式([)の化合物が式(至)の
カルボン酸の存在下に、二酸化セレンで酸化されると、
通常、式(1)および式(「)の化合物が同時に生成さ
れる。その比率は、反応条件、ことに式(5)のカルボ
ン鈑の種類、二酸化セレンの量等により大礒に変わり、
たとえばギ酸を使用すると、式(旺)の化合物の生成量
が大きくなる。式(ff)の化合物は新規であり、それ
自体も若干の殺ダニ活性を有するが、13位にカルボニ
ル基もしくはホルミル基等の反応性に富む官能基を有し
ているので、さらに活性が強い化合物へ誘導するための
中間体としても重要である。
In the method of the invention, when a compound of formula ([) is oxidized with selenium dioxide in the presence of a carboxylic acid of formula (to),
Usually, the compounds of formula (1) and formula ('') are produced simultaneously.The ratio varies depending on the reaction conditions, especially the type of carvone plate of formula (5), the amount of selenium dioxide, etc.
For example, the use of formic acid results in the production of a large amount of the compound of formula (O). The compound of formula (ff) is new and has some acaricidal activity itself, but it has even stronger activity because it has a highly reactive functional group such as a carbonyl group or formyl group at the 13th position. It is also important as an intermediate for deriving compounds.

式(1)の化合物の取得を目的とする場合には、それ故
、本発明の方法の反応物(通常は、前述のとおり、式(
ff)の化合物との混合物である)を、単離しもしくは
単離することなしに、加水分解反応に付して、その全Q
t式(I)の化合物とすることができる。
If the aim is to obtain a compound of formula (1), the reactants of the process according to the invention (usually, as mentioned above, of the formula (
ff) is subjected to a hydrolysis reaction, with or without isolation, to obtain its total Q
It can be a compound of formula (I).

式(■〕の化合物の取得を目的とする場合には、本発明
の方法の反応物を、カレム・クロマトグラフィー等の通
常の精製方法で分離・精製すればよい。
When the purpose is to obtain a compound of formula (■), the reactant of the method of the present invention may be separated and purified by a conventional purification method such as Calem chromatography.

式(1)と式(ト)の化合物の反応において、式(イ)
のカルボン酸は、式(II)の化合物1モルに対して通
常1モル以上使用される。式(ト)のカルボン酸を大過
剰量用いて、反応溶媒を兼ねても差支えなく、このこと
は本発明の有利な態様である。
In the reaction of compounds of formula (1) and formula (g), formula (a)
The carboxylic acid is usually used in an amount of 1 mol or more per 1 mol of the compound of formula (II). The carboxylic acid of formula (g) may be used in large excess to serve as a reaction solvent, and this is an advantageous aspect of the present invention.

溶媒として、前記カルボン酸以外のものを使用するとき
は、本反応に不活性である限り、ことに限定はなく、た
とえば、ヘキサン、べ/ゼンのような炭化水素類、塩化
メチレン、クロロホルムのようなハロゲン化炭化水素り
、ジエチルエーテル、テトラヒドロフラン、ジオキサン
のようなエーテル類、メタノール、エタノールのような
アルコール類、酢酸エチル、酢酸アミルのようなエステ
ル類、NjN−ジメチルホルムアミド、N、N−ジメチ
ルアセトアミドのようなアミド類、ジメチルスルホキシ
ドおよび水、並びにこれらの溶媒の混合物があげられる
。     。
When using a solvent other than the above-mentioned carboxylic acid, there is no particular limitation as long as it is inert to this reaction. For example, hydrocarbons such as hexane, benzene, methylene chloride, chloroform, etc. halogenated hydrocarbons, ethers such as diethyl ether, tetrahydrofuran and dioxane, alcohols such as methanol and ethanol, esters such as ethyl acetate and amyl acetate, NjN-dimethylformamide, N,N-dimethylacetamide Amides such as dimethyl sulfoxide and water, as well as mixtures of these solvents. .

二酸化セレンの使用量は、式(II)の化合物1モ  
  □ルに対して、通常1ないし10倍モル、好適には
1ないし3倍モルである。
The amount of selenium dioxide used is 1 mol of the compound of formula (II).
The amount is usually 1 to 10 times, preferably 1 to 3 times, per mole.

反応温度および反応時間はとぐに限定はなく、0℃ない
し80℃、好適には、室温ないし、若干加温下に30分
ないし一昼夜程度、反応が行なわれる。
The reaction temperature and reaction time are not immediately limited, and the reaction is carried out at 0° C. to 80° C., preferably at room temperature or with slight heating for about 30 minutes to all day and night.

反応終了後、反応物は通常の方法で処理される。たとえ
ば、反応液からセレン化合物eF去し、P液から適当な
有機溶媒で生成物を抽出し、濃縮することにより、式(
1)および(It)の混合物が粗生成物として得られる
After the reaction is complete, the reactants are treated in a conventional manner. For example, by removing the selenium compound eF from the reaction solution, extracting the product from the P solution with an appropriate organic solvent, and concentrating it, the formula (
A mixture of 1) and (It) is obtained as a crude product.

所望により式(「)の化合物を加水分解するには、上記
の反応混合物を単離し、もしくは単離することなく、通
常の加水分解反応に付せばよい。
In order to optionally hydrolyze the compound of formula ('), the above reaction mixture may be isolated or subjected to a conventional hydrolysis reaction without isolation.

式(1)の化合物は、通常の加水公簿条件下では悪影響
を受けることなく、そのまま保たれるので、加水分解反
応に際して、事前に単、娠しておく必要はない。
Since the compound of formula (1) remains as it is without being adversely affected under normal hydrolysis conditions, there is no need to pre-prepare it in advance for the hydrolysis reaction.

加水分解は、酸もしくに塩基の存在下に溶媒中で行なわ
れる。使用される蛾としては、たとえば、塩酸、硝酸、
硫酸等の鉱酸、好ましくは塩酸が挙げられ、また、塩基
としては、酢酸ナトリウム、酢酸カリウム、炭酸水素ナ
トリウム、炭酸ナトリウム、炭酸力νラム等があげられ
る。
Hydrolysis is carried out in a solvent in the presence of an acid or a base. For example, hydrochloric acid, nitric acid,
Examples include mineral acids such as sulfuric acid, preferably hydrochloric acid, and examples of bases include sodium acetate, potassium acetate, sodium bicarbonate, sodium carbonate, and carbonate.

溶媒は反応に関与しないものであれば、とくに限定はな
く、上記反応に使用されたカルボン酸が引続き使用でき
る他、メタノール、エタノール、プロパツールのような
アルコール類、ジエチルエーテル、テトラヒドロフラン
、ジオキサンのようなエーテル類および水、並びにこれ
らの溶媒の混合物が使用される。
The solvent is not particularly limited as long as it does not participate in the reaction, and the carboxylic acid used in the above reaction can be used, as well as alcohols such as methanol, ethanol, propatool, diethyl ether, tetrahydrofuran, and dioxane. ethers and water, as well as mixtures of these solvents, are used.

反応温度および反応時間はとくに限定はなく、通常、−
10℃ないし100℃、好適には0℃ないし50℃で3
0分ないし15時間、好適には1ないし8時間反応が行
なわれる。
The reaction temperature and reaction time are not particularly limited, and are usually -
3 at 10°C to 100°C, preferably 0°C to 50°C.
The reaction is carried out for 0 minutes to 15 hours, preferably 1 to 8 hours.

加水分解後、式(1)の化合物は、常法に従って反応混
合物より容易に採取することができる。−たとえば、反
応混合物を水に注ぎ、必要ならば不溶物kP態別後F液
を中和し、水不混和性溶媒で抽出する。抽出液を乾燥後
、溶媒を留去することにより、式(1)の化合物が得ら
れる。さらに必要に応じて、式(I)の化合物は再結晶
、カラムクロマトグラフィー等の常法によって′!W製
することもできる。
After hydrolysis, the compound of formula (1) can be easily collected from the reaction mixture according to conventional methods. - For example, pour the reaction mixture into water, if necessary after separating the insolubles kP, neutralize solution F and extract with a water-immiscible solvent. After drying the extract, the solvent is distilled off to obtain the compound of formula (1). Furthermore, if necessary, the compound of formula (I) can be purified by conventional methods such as recrystallization and column chromatography. It can also be made of W.

本発明の方法を実施例により更に具体的に説明する。The method of the present invention will be explained in more detail with reference to Examples.

実施例1゜ 5−ケトミルベマイシンA4(2,Of )のギ酸溶液
(2smz)に二酸化セレン(0,56P)を加え、4
0℃で2時間攪拌する。反応終了後、反応液にセ2イト
ヲ加え、セレン化合物をr別する。FMを水にあけ、酢
酸エチルで抽出し、抽出液を硫酸マグネシウムで乾燥後
濃縮すると、一部13−ヒドロキシ体を含む13−ホル
ミルオキシ−5−ケトミルベマイシンA4の粗生成物を
得る。この粗生成物に、メタノール(120m)、2規
足塩酸水(20ゴ)、1.4−ジオキサン(30プ)を
加え、室温で5時間撹拌する。反応終了後、反応液を水
にあけ、酢酸エチルで抽出する。
Example 1 Selenium dioxide (0,56P) was added to a formic acid solution (2smz) of 5-ketomilbemycin A4 (2,Of).
Stir at 0°C for 2 hours. After the reaction is complete, add selenium to the reaction solution to separate the selenium compound. The FM is poured into water, extracted with ethyl acetate, and the extract is dried over magnesium sulfate and concentrated to obtain a crude product of 13-formyloxy-5-ketomilbemycin A4 containing a portion of the 13-hydroxy compound. To this crude product, methanol (120 ml), 2 liters of hydrochloric acid (20 ml), and 1,4-dioxane (30 ml) were added, and the mixture was stirred at room temperature for 5 hours. After the reaction is complete, the reaction solution is poured into water and extracted with ethyl acetate.

有機層を硫酸マグネシウムで乾燥後、濃縮し、残金をカ
ラムクロマトグラフィーにより精製すると、掲記化合物
1.03 fを得る。収率50チ。
The organic layer is dried over magnesium sulfate, concentrated, and the residue is purified by column chromatography to obtain the title compound 1.03 f. Yield: 50 cm.

質量スペクトル(m/  );5ss(u+)。Mass spectrum (m/ ); 5ss (u+).

538(M+−18) 核磁気共鳴スペクトル(CDCt、)δ91m:1.5
9 (s 、 3H、C14CH5)1゜8 B (s
 、3 H# Ca CH3)3.0〜3.15 (m
 、 IH、C25H)3.5〜3、i55 (m 、
 2H、C17H,C2H)3.74((LjII(、
C43I(、J−10H2)1.8f+(ε、 IH、
C6H) 4.0 (a 、I Hz C70H)4.65〜t8
5(m、2a、c8ci2)5.2〜5.9 (m s
 5 a 、c 1sa + C1q Hx c 1 
+ Hs C1oa rC2H) 6−48 (t + C3H) 5.55(t 、 C3H)            
     。
538 (M+-18) Nuclear magnetic resonance spectrum (CDCt,) δ91m: 1.5
9 (s, 3H, C14CH5) 1°8 B (s
, 3 H# Ca CH3) 3.0~3.15 (m
, IH, C25H) 3.5-3, i55 (m,
2H, C17H, C2H) 3.74 ((LjII(,
C43I (, J-10H2) 1.8f+(ε, IH,
C6H) 4.0 (a, I Hz C70H) 4.65~t8
5 (m, 2a, c8ci2) 5.2-5.9 (m s
5 a, c 1sa + C1q Hx c 1
+ Hs C1oa rC2H) 6-48 (t + C3H) 5.55 (t, C3H)
.

実施例2 5−ケトミルベマイシンD(0,56P)の酢酸溶液(
10WLlりに二酸化セレン(0,22f )を加え、
40℃で1時間攪拌する。反応終了後、反応液にセライ
)1−加え、セレン化合物をP別する。P液を水にあけ
、酢酸エチルで抽出し、抽出液を重そう水で洗い硫酸マ
グネシウムで乾燥濃縮後、残金をカラムクロマトグラフ
ィーにより精製すると、13−アセトキシ−5−ケトミ
ルベマイシンDQ、12f(収率21チ)と13−ヒド
ロキシ−5−ケ)ミルベマイシンpo、1ar(収率3
2%)を得る。
Example 2 Acetic acid solution of 5-ketomilbemycin D (0,56P) (
Add selenium dioxide (0.22f) to 10WL,
Stir at 40°C for 1 hour. After the reaction is completed, selenium) 1- is added to the reaction solution, and P is separated from the selenium compound. The P solution was poured into water, extracted with ethyl acetate, the extract was washed with deuterated water, dried over magnesium sulfate, concentrated, and the residue was purified by column chromatography to obtain 13-acetoxy-5-ketomilbemycin DQ, 12f (harvested). (yield 21) and 13-hydroxy-5-ke) milbemycin po, 1ar (yield 3
2%).

13−アセトキシ 赤外線吸収スペクトルν  :34BQ、1740゜a
x 1715.15i85,1460cIn ’ifスペク
)y(rn/ )二612(u+)。
13-acetoxy infrared absorption spectrum ν: 34BQ, 1740°a
x 1715.15i85, 1460cIn'ifspec)y(rn/)2612(u+).

594(M”−18) 核磁気共鳴スペクトル(CDC43)δQpm ’1.
55 (s 、 3H、C14CC14C,90(s 
、 3H、C4CH5)2.05(a)および2.07
 (s) (3H−CCH3)6−57 (m II 
Hs CsH)13−ヒドロキシ体 nujol  。
594 (M”-18) Nuclear magnetic resonance spectrum (CDC43) δQpm '1.
55 (s, 3H, C14CC14C, 90(s
, 3H, C4CH5) 2.05(a) and 2.07
(s) (3H-CCH3)6-57 (m II
Hs CsH) 13-hydroxy form nujol.

赤外線吸収スペクトル ν   、3450゜aX 1735.1715,1580crn ’質量スペクト
ル(”/):5γO(M+)。
Infrared absorption spectrum ν, 3450°aX 1735.1715,1580crn' Mass spectrum (''/): 5γO (M+).

552(M+−18) 核磁気共鳴スペクトル(cDcz3)δppm ’1、
58 (s 、 3H、C14CC14C89(m s
 3 H+ C4CH3)4−6〜4−8 (ma 2
 H−Ca CH2)5.23 (t 、 c15H) s、3〜5.45(m、cllH,cl、H)5.6〜
5.9 (ffi 、 C9H,C4゜H,C,5H)
6−57 (m 1CsH) i 52 (m 、CsH) 上記の方法により得られる13−アセトキシ−5−ケト
ミルベマイシンD(0,10F)に、メタノール(20
d)、2規定塩酸(5M)、1,4−ジオキサン(10
m)を加え、50℃で5時間加熱攪拌する。反応終了後
、13−ホルミルオキシ−5−ケトミルベマイシンの加
水分解と同様の後処理によって、0.015Pの13−
ヒドロキシ−5−ケトミルベマイシンDを得る。
552 (M+-18) Nuclear magnetic resonance spectrum (cDcz3) δppm '1,
58 (s, 3H, C14CC14C89 (m s
3 H+ C4CH3) 4-6 to 4-8 (ma 2
H-Ca CH2) 5.23 (t, c15H) s, 3-5.45 (m, cllH, cl, H) 5.6-
5.9 (ffi, C9H, C4°H, C, 5H)
6-57 (m 1CsH) i 52 (m , CsH) Methanol (20
d), 2N hydrochloric acid (5M), 1,4-dioxane (10
Add m) and heat and stir at 50°C for 5 hours. After the reaction, 0.015P of 13-
Hydroxy-5-ketomilbemycin D is obtained.

実施例3゜ 5−ケトミルベマイシンD(0,56F)のギ酸溶液(
10M)に、二酸化セレン(0,17F)を加え、40
℃で2時間攪拌する。反応終了後、反応液にセライトを
加え、セレン化合物’(i−F別した後、P液を水にあ
け、酢酸エチルで抽出する。抽出液の濃縮残渣をシリカ
ゲルカラムクロマトグラフィーにより8製して、a、2
r?c収率44%)の13−ホルミル体と、0.02 
Fの13−ヒドロキシ体を得る。
Example 3 A solution of 5-ketomilbemycin D (0,56F) in formic acid (
Add selenium dioxide (0.17F) to 40
Stir at ℃ for 2 hours. After the reaction was completed, celite was added to the reaction solution, and after separating the selenium compound' (i-F), the P solution was poured into water and extracted with ethyl acetate.The concentrated residue of the extract was purified by silica gel column chromatography. ,a,2
r? c yield 44%) and 0.02
The 13-hydroxy form of F is obtained.

13−ホルミル体 赤外線吸収スペクトル ν  :355G。13-formyl body Infrared absorption spectrum ν: 355G.

a1 1730.1685.1460cm’ 質量スペクトル(I11/  ):5913CM+)。a1 1730.1685.1460cm' Mass spectrum (I11/): 5913CM+).

58G(M+−18) 核磁気共鳴スペクトル(CDC73)δppm ’1.
56 (s 、 3H、C14CH5)L 91 (m
+ 3 Hr C4CHs )5.06(d、IH,C
13H,J−10H2)5.35〜5.45 (m 、
 3H、C11H,C1,H,C15H)5、8〜5.
9 (m 、 2 H、C’9HjC4゜H)$−58
(m + I HICs H)8.09 (m 、 i
H、−0CHO)上記の方法により得られる13−ホル
ミルオキシ−5−ケトミルベマイシンD(0,2(1)
に、メタ/−#(25d)、1規定塩酸水(10mJ)
、1.4−ジオキサン(,15rR1りi加え、室温で
−晩攪拌医、反応液を水にあけ、酢酸エチルで抽出する
。抽出液の濃縮残渣をシリカゲルカラムクロマトグラフ
ィーにより精製して、014?の    113−ヒド
ロキシ−5−ケトミルベマイシンDを得る。
58G (M+-18) Nuclear magnetic resonance spectrum (CDC73) δppm '1.
56 (s, 3H, C14CH5)L 91 (m
+ 3 Hr C4CHs ) 5.06 (d, IH, C
13H, J-10H2) 5.35-5.45 (m,
3H, C11H, C1,H, C15H)5, 8-5.
9 (m, 2 H, C'9HjC4゜H) $-58
(m + I HICs H)8.09 (m , i
H, -0CHO) 13-formyloxy-5-ketomilbemycin D (0,2(1)
, meta/-# (25d), 1N hydrochloric acid water (10mJ)
, 1,4-dioxane (15rR1) was added, stirred overnight at room temperature, the reaction solution was poured into water, and extracted with ethyl acetate.The concentrated residue of the extract was purified by silica gel column chromatography. 113-hydroxy-5-ketomilbemycin D is obtained.

手続補正書(自発) 昭和60年10月γ日 昭和59年特許願第225551号 2、発明の名称 13−置換−5−ケトミルベマイシン類およびその製造
法;3.補正をする者 事件との関係 特許出、;碩人 住所 〒103東京都中央区日本僑本町3丁目1番地の
6名称    (185)三共株式会社 代表者 取締役社長  河村喜典 4、代理人 居所 〒140東京部品川区広町1丁目2番58号三共
株式会社内 6、補正の対象 1、明細書12頁1行目、同13頁8行目、同15頁1
4行目および同16頁16行目に「残渣」とあるのを、
「残渣」に訂正する。
Procedural amendment (spontaneous) October 1985, Patent Application No. 225551, filed in 1982, 2, title of the invention 13-Substituted-5-ketomilbemycins and their manufacturing process; 3. Relationship with the case of the person making the amendment: Patent issued; Address: 6, 3-1 Nipponkakuhonmachi, Chuo-ku, Tokyo 103 (185) Sankyo Co., Ltd. Representative Director and President Yoshinori Kawamura 4; Agent residence: 140 Sankyo Co., Ltd., 1-2-58 Hiromachi, Honbunagawa-ku, Tokyo 6, subject of amendment 1, page 12 line 1 of the specification, page 13 line 8, page 15 line 1
The word "residue" on line 4 and line 16 on page 16,
Corrected to "residue".

2 明、iia!12頁8行目rr3.a〜3.15(
m、IH。
2 Ming, ia! Page 12, line 8 rr3. a~3.15(
m, IH.

C25H) Jとあるのを、「3−08 (a t−I
 H# C25H−J−λ6,9.7Hz)Jと訂正す
る。
C25H) J is replaced with “3-08 (a t-I
H# C25H-J-λ6, 9.7Hz) Correct as J.

ふ 明細書12頁14行ないし17行目に「5,2〜5
.9(m、5H1c15H゛、c19H1c11H1c
1oH。
F. On page 12 of the specification, lines 14 to 17, “5, 2 to 5
.. 9 (m, 5H1c15H゛, c19H1c11H1c
1oH.

C,H) 6.48(t jC3H)  5.55(t
 、C31()Jとあるのを、r 5.25(t、IH
,C45H、J−11,THz)5.35〜5.5(m
、2H,cl、a 、 C1,H) 5.75〜5.9
(m 、 2 H、C4゜H、C,H)  6.55(
m、IH。
C, H) 6.48 (t jC3H) 5.55 (t
, C31()J, r 5.25(t, IH
, C45H, J-11, THz) 5.35 to 5.5 (m
, 2H, cl, a, C1, H) 5.75-5.9
(m, 2H, C4°H, C,H) 6.55(
m, IH.

C3H)」に訂正する。C3H)”.

Claims (2)

【特許請求の範囲】[Claims] (1)一般式(III) ▲数式、化学式、表等があります▼(III) (式中、R^1はメチル基、エチル基、イソプロピル基
またはsec−ブチル基を示す)で表わされる化合物を
、一般式(IV) R^2−COOH(IV) (式中、R^2は水素原子または低級アルキル基を示す
)で表わされるカルボン酸の存在下、二酸化セレンで処
理して、一般式( I )または(II)▲数式、化学式、
表等があります▼( I ) ▲数式、化学式、表等があります▼(II) (式中、R^1およびR^2は、前記したものと同意義
である)で表わされる化合物とし、必要に応じて、一般
式(II)の化合物を加水分解することを特徴とする、一
般式( I )で表わされる化合物の製造法。
(1) General formula (III) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (III) (In the formula, R^1 represents a methyl group, ethyl group, isopropyl group or sec-butyl group) , general formula (IV) R^2-COOH (IV) (wherein, R^2 represents a hydrogen atom or a lower alkyl group) by treatment with selenium dioxide in the presence of a carboxylic acid represented by the general formula (IV) (where R^2 represents a hydrogen atom or a lower alkyl group). I) or (II)▲Mathematical formula, chemical formula,
There are tables, etc.▼(I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(II) (In the formula, R^1 and R^2 have the same meanings as above) A method for producing a compound represented by general formula (I), which comprises hydrolyzing a compound represented by general formula (II) according to the method.
(2)一般式(II) ▲数式、化学式、表等があります▼(II) (式中、R^1はメチル基、エチル基、イソプロピル基
またはsec−ブチル基を示し、R^2は水素原子また
は低級アルキル基を示す)で表わされる化合物。
(2) General formula (II) ▲Mathematical formulas, chemical formulas, tables, etc.▼(II) (In the formula, R^1 represents a methyl group, ethyl group, isopropyl group, or sec-butyl group, and R^2 represents hydrogen. atom or lower alkyl group).
JP22555184A 1984-10-26 1984-10-26 13-substituted-5-ketomilbemycin and its preparation Granted JPS61103884A (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP22555184A JPS61103884A (en) 1984-10-26 1984-10-26 13-substituted-5-ketomilbemycin and its preparation
IL76816A IL76816A (en) 1984-10-26 1985-10-24 Process for preparing 13-hydroxy-5-ketomilbemycin
IL85820A IL85820A (en) 1984-10-26 1985-10-24 13-substituted-5-ketomilbemycin derivatives and processes for the preparation thereof
AU49045/85A AU574852B2 (en) 1984-10-26 1985-10-24 13 - acyloxy - 5 - ketomilbemycin derivatives and preparation of 13 - hydroxy - 5 - ketomilbemycin derivatives
ZA858197A ZA858197B (en) 1984-10-26 1985-10-25 Process for preparing milbemycin derivatives and certain novel compounds employed therein
ES548244A ES8703475A1 (en) 1984-10-26 1985-10-25 Process for preparing milbemycin derivatives and certain novel compounds employed therein.
NZ213972A NZ213972A (en) 1984-10-26 1985-10-25 13-hydroxy-5-ketomilbemycins: derivatives thereof
DK492785A DK161705C (en) 1984-10-26 1985-10-25 PROCEDURE FOR PREPARING A 13-HYDROXY-5-KETOMIL BEMYCINE DERIVATIVE
KR1019850007942A KR930005333B1 (en) 1984-10-26 1985-10-26 Process for preparing milbemycin derivatives
CA000494017A CA1267890A (en) 1984-10-26 1985-10-28 Process for preparing milbemycin derivatives and certain compounds employed therein
EP85307782A EP0184308B1 (en) 1984-10-26 1985-10-28 Process for preparing milbemycin derivatives and certain novel compounds employed therein
DE8585307782T DE3574974D1 (en) 1984-10-26 1985-10-28 METHOD FOR PRODUCING MILBEMYCINE DERIVATIVES AND SOME DERIVATIVES USED IN THIS METHOD.
AT85307782T ATE49001T1 (en) 1984-10-26 1985-10-28 PROCESSES FOR THE MANUFACTURE OF MILBEMYCIN DERIVATIVES AND SOME DERIVATIVES USED IN THIS PROCESS.
US07/115,642 US4835290A (en) 1984-10-26 1987-10-26 Process for preparing 13-hydroxy-5-ketomibemycin derivatives having acaricidal, insecticidal and anthelmintic activity
IL85820A IL85820A0 (en) 1984-10-26 1988-03-23 13-substituted-5-ketomilbemycin derivatives and processes for the preparation thereof
DK267190A DK267190A (en) 1984-10-26 1990-11-07 13-substituted-5-ketomilbemycin derivatives
US07/644,880 US5208349A (en) 1984-10-26 1991-01-24 Process for preparing milbemycin derivatives and certain novel compounds employed therein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22555184A JPS61103884A (en) 1984-10-26 1984-10-26 13-substituted-5-ketomilbemycin and its preparation

Publications (2)

Publication Number Publication Date
JPS61103884A true JPS61103884A (en) 1986-05-22
JPH0477752B2 JPH0477752B2 (en) 1992-12-09

Family

ID=16831062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP22555184A Granted JPS61103884A (en) 1984-10-26 1984-10-26 13-substituted-5-ketomilbemycin and its preparation

Country Status (2)

Country Link
JP (1) JPS61103884A (en)
ZA (1) ZA858197B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63238083A (en) * 1987-03-16 1988-10-04 メルク エンド カムパニー インコーポレーテツド Avermectin derivative

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63238083A (en) * 1987-03-16 1988-10-04 メルク エンド カムパニー インコーポレーテツド Avermectin derivative
JP2669635B2 (en) * 1987-03-16 1997-10-29 メルク エンド カムパニー インコーポレーテツド Avermectin derivative

Also Published As

Publication number Publication date
ZA858197B (en) 1987-07-29
JPH0477752B2 (en) 1992-12-09

Similar Documents

Publication Publication Date Title
FR1449628A (en) Process for the preparation of deacylated polynuclear indoles, in particular esters of the deacetyl-vincaleucoblastine and deacetylvincristine series
FR2517302A1 (en) ESTERS AND AMIDES OF 13 14-BISDEHYDROPROSTAGLANDINS
HIRAI et al. Syntheses and reactions of 2-substituted thiazolidines
JP2733583B2 (en) Method for producing ceramide
JPS61103884A (en) 13-substituted-5-ketomilbemycin and its preparation
US4851588A (en) Novel process for the preparation of bronopol
US3910958A (en) Process for preparing arylacetic acids and esters thereof
JPS6317077B2 (en)
JPH0662591B2 (en) Novel thioproline derivative
Shin et al. Syntheses of picroroccelin diastereomers and their regioisomers
JP3249847B2 (en) Method for producing Z-cyclohexylideneacetic acid derivative
BE884977A (en) NOVEL N-PHENYL-BENZAMIDES USEFUL IN THE TREATMENT OF MAMMALIAN INFLAMMATION AND PAIN
JP2718715B2 (en) 9,10-seco-cycloartane derivatives
JPS62252788A (en) 13-hyroxymilbemycin derivative and production thereof
EP0538436A1 (en) Novel quaternary ammonium salts, process for obtaining same and pharmaceutical compositions containing them
JPS59205365A (en) Manufacture of 4-acetyl-2-substituted-imidazole compound andintermediate
FR2569194A1 (en) PROCESS FOR THE PREPARATION OF AMINOLACTONE
JP3777407B2 (en) Method for producing carboxylic acid derivative
US4608442A (en) Process for preparing 4-hydroxy-2-cyclopentenones
JP2869745B2 (en) Optically active dichlorlactone compound, method for producing the same, and method for producing optically active diol compound using the same
JP2833672B2 (en) Method for producing β-ketonitrile
FR2505332A1 (en) COMPOUNDS FOR THE SYNTHESIS OF PROSTAGLANDINS AND PROSTACYCLINS CONTAINING NITROGEN AND PROCESS FOR THEIR PREPARATION
JPS58121260A (en) 1-azidocyclopropanecarboxylic acid derivative and preparation thereof
JPH03130292A (en) Oxazoloisoquinoline compound
JPS5842871B2 (en) Novel sesquiterpene compounds and their production method